There’s more to the testy emails from cardiologist John Kastelein to Schering-Plough over the handling of the controversial study of cholesterol drug Vytorin. And now we can peek at the rest.
Today the Merck/Schering-Plough joint venture that sells Vytorin made public more details of an email exchange that drew attention yesterday when Sen. Chuck Grassley released [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment